Navigation Links
HYCOR Establishes Center Of Operations In Kassel, Germany To Provide Dedicated Support To European Distributors And Customers
Date:9/18/2012

GARDEN GROVE, Calif., Sept. 18, 2012 /PRNewswire/ -- HYCOR Biomedical, Inc., a leading manufacturer and marketer of in vitro diagnostic products for the global allergy, autoimmune and urinalysis markets, today announced the opening of its European center of operations located in Kassel, Germany. The facility primarily houses field and technical service as well as customer service functions.

"As we continue to branch out internationally, we are thrilled to reestablish our physical presence in Europe with this new facility in Kassel, Germany," said Dick Aderman, CEO, HYCOR. "The opening of this facility is part of our global growth strategy and marks an important step in strengthening our support and commitment to EMEA (Europe, the Middle East and Africa) customers. The facility will be instrumental in handling current and future distributor and customer needs."

The new center of operations, which opened in early August, supports HYCOR's expansion in EMEA and demonstrates HYCOR's commitment and dedication to this important market.

Contact information
HYCOR Europe / Biocrest B.V.
Waldauer Weg 84
34253 Kassel - Lohfelden
Germany
Phone: +49 561 816 7000 - 0
Fax: +49 561 816 7000 - 99
Customer Service: cseurope@hycorbiomedical.com
Technical & Application Service: techserviceseurope@hycorbiomedical.com   

About HYCOR Biomedical, Inc.
Founded in 1981, HYCOR is a global manufacturer and marketer of in vitro diagnostics products. Since its founding, HYCOR has expanded its presence into urinalysis, allergy and autoimmune products used in clinical laboratories, hospitals and doctors' offices worldwide. Among its products, HYCOR markets the HYTEC™, KOVA® and AUTOSTAT™ brands. The company is focused on delivering products that provide the highest value to clinicians through innovation, reliability and customer service. For more information, please visit www.hycorbiomedical.com.

About Linden LLC
Linden is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden's strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden's portfolio includes BarrierSafe Solutions International, Behavioral Centers of America, Corpak MedSystems, Drayer Physical Therapy Institute, HYCOR Biomedical, and Ranir. For additional information, please visit www.lindenllc.com.


'/>"/>
SOURCE HYCOR Biomedical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CMC Biologics Establishes Commercial Presence in Japan through Strategic Agreement with Innomedica
2. Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA149
3. Pharmatek Establishes the Pharmatek Foundation
4. Varian Medical Systems Establishes Subsidiary in South Korea
5. OncoSec Establishes Clinical Site for Its Phase II Merkel Cell Carcinoma Trial at University of California San Francisco (UCSF)
6. Quest Diagnostics Establishes Unique Healthcare Identifier to Improve Access to Vital Patient Health Information; 80 Million Patient IDs Created to Date
7. Surgical Equipment Market to 2018 - Increased Access to Ambulatory Surgical Centers to Drive Outpatient Surgery Volumes
8. Johnson & Johnson Announces Plans to Establish Innovation Centers
9. Comprehensive Care Corporation Signs Agreement With WellDyneRx as Part of CompCares New Pharmacy Savings Center Program
10. Putnam Community Medical Center Selects Optimal Radiology
11. Executive Insight Hosts Webinar "The Hospital Pharmacy as a Revenue Center"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... March 27, 2017  iCAD (Nasdaq: ICAD), an ... and radiation therapy for the early identification and ... Detection received Premarket Approval (PMA) from the U.S. ... is a first-of-its-kind, concurrent-read computer aided detection solution ... latest innovation available on the PowerLook® Breast Health ...
(Date:3/27/2017)... 27, 2017  PhaseRx, Inc. (NASDAQ: PZRX), a ... liver diseases in children, today reported financial results ... December 31, 2016 and provided an update on ... to make progress during the fourth quarter of ... our non-human primate safety study, and with our lead ...
(Date:3/24/2017)... PUNE, India , March 24, 2017 Abdominal ... to reach $2,614 million by 2022, Globally, registering a CAGR of 5.1% from 2016 ... revenue, and is projected to dominate the market during the study period. ... ... Logo ...
Breaking Medicine Technology:
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... patients for clear braces. People who want straight teeth without the extensive time ... in Clearwater, FL, without acquiring a referral. A custom-designed series of virtually ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... site attention and engagement over the household brands of Top-20 pharma by optimizing ... discuss how partnering with the right outsourcing payments provider can provide the technology, ...
(Date:3/27/2017)... ... ... Buzzies parent company, The TouchPoint Solution’s CEO and co-founder, Vicki Mayo, was recently ... Mayo will present her pitch about the lifestyle wearable devices, Buzzies live ... ignites bold ideas by providing women access to the tools, training and networks needed ...
(Date:3/27/2017)... ... March 27, 2017 , ... American Veterinarian™, the leading multimedia ... medicine, announces the launch of Veterinarian’s Money Digest™, a business and financial resource ... of American Veterinarian™. , “We look forward to launching Veterinarian’s Money ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... enables researchers to pursue the recent RNA methylation “gold rush” with their established ... of the newfound characteristics of N6-methyladenosine, or m6A , RNA methylation has ...
Breaking Medicine News(10 mins):